Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Compounds in development (PDF 0.1 MB) section of the 2025 Annual Report  

Show Filters
Showing 38 results
  • AAA601
    Lutathera®
    GEPNET, pediatrics
    Oncology: Solid Tumors Phase 2 Radioligand therapy target SSTR
  • AAA603
    177Lu-NeoB
    Multiple solid tumors
    Oncology: Solid Tumors Phase 2 ≥ 2029 Radioligand therapy target GRPR
    Lead Indication
  • AAA617
    Pluvicto®
    Metastatic hormone sensitive prostate cancer (mHSPC)
    Oncology: Solid Tumors Registration Radioligand therapy target PSMA
    Supplementary Indication
  • AAA817
    225Ac-PSMA-617
    Metastatic castration-resistant prostate cancer (mCRPC)
    Oncology: Solid Tumors Phase 3 ≥ 2029 Radioligand therapy target PSMA
  • AIN457
    Cosentyx®
    Polymyalgia rheumatica
    Immunology Phase 3 2026 IL17A inhibitor (Anti-interleukin-17 monoclonal antibody)
    Supplementary Indication
  • AMG334
    Aimovig®
    Migraine, pediatrics
    In-market Brands and Global Health Phase 3 2028 CGRPR antagonist
    Supplementary Indication
  • BAF312
    Mayzent®
    Multiple sclerosis, pediatrics
    Neuroscience Phase 3 2027 S1P1,5 receptor modulator
    Supplementary Indication
  • EDI048
    EDI048
    Cryptosporidiosis
    In-market Brands and Global Health Phase 2 CpPI(4)K inhibitor
    Lead Indication
  • KAE609
    cipargamin
    Malaria severe
    In-market Brands and Global Health Phase 2 ≥ 2029 PfATP4 inhibitor
    Lead Indication
  • KAE609
    cipargamin
    Malaria, uncomplicated
    In-market Brands and Global Health Phase 2 ≥ 2029 PfATP4 inhibitor
    Supplementary Indication
  • KJX839
    Leqvio®
    CVRR (primary prevention)
    Cardiovascular, Renal and Metabolic Phase 3 ≥ 2029 siRNA (regulation of LDL-C)
    Supplementary Indication
  • KJX839
    Leqvio®
    CVRR (secondary prevention)
    Cardiovascular, Renal and Metabolic Phase 3 2027 siRNA (regulation of LDL-C)
    Supplementary Indication
  • KJX839
    Leqvio®
    Hyperlipidemia, pediatrics
    Cardiovascular, Renal and Metabolic Registration siRNA (regulation of LDL-C)
    Supplementary Indication
  • KLU156
    Ganaplacide + lumefantrine
    Malaria, uncomplicated
    In-market Brands and Global Health Phase 3 2026 Non-artemisinin plasmodium falciparum inhibitor
    Lead Indication
  • LNP023
    Fabhalta®
    C3 glomerulopathy, pediatrics
    Cardiovascular, Renal and Metabolic Phase 3 CFB inhibitor
  • LNP023
    Fabhalta®
    IC-MPGN
    Cardiovascular, Renal and Metabolic Phase 3 ≥ 2029 CFB inhibitor
    Supplementary Indication
  • LNP023
    Fabhalta®
    Lupus Nephritis
    Cardiovascular, Renal and Metabolic Phase 2 CFB inhibitor
  • LNP023
    Fabhalta®
    Atypical Hemolytic Uremic Syndrome (aHUS)
    Oncology: Hematology Phase 3 ≥ 2029 CFB inhibitor
    Supplementary Indication
  • LNP023
    Fabhalta®
    iAMD
    Others Phase 2 CFB inhibitor
  • LOU064
    Rhapsido®
    Chronic spontaneous urticaria, pediatrics
    Immunology Phase 3 BTK inhibitor
Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.